Avonex
Trovati 3 articoli
- FDA has approved the reintroduction of Tysabri in relapsing multiple sclerosis
- The FDA ( U.S. Food and Drug Administration ) has approved the reintroduction of Tysabri ( Natalizumab ) as a monotherapy treatment for relapsing forms of multiple sclerosis to slow the progression of disability and reduce the frequency of clinical relapses. TYSABRI will be available upon th... (Leggi Articolo)
- Interferon beta-1a plus Natlizumab reduces multiple sclerosis relapse rate
- One-year data from the Phase III SENTINEL trial, presented at the 57th Annual Meeting - American Academy of Neurology ( AAN ), demonstrated that when Natalizumab ( Tysabri ) was added to Interferon beta-1a ( Avonex ) in patients with relapsing forms of multiple sclerosis ( MS ), the annualized cl... (Leggi Articolo)
- Interferon beta-1a associated with cases of severe liver damage
- Avonex ( Interferon beta-1a ) is approved for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. FDA ( Food and Drug Administration ) and Biogen informed healthcare professio... (Leggi Articolo)
